Table 3 Adjusted OR for all the other variables
From: Vision loss in patients with giant cell arteritis treated with tocilizumab
Permanent vision loss at baseline | Crude OR (95%-CI) | p-value | Adjusted OR (95%-CI) | p-value | |
|---|---|---|---|---|---|
Age at diagnosis | 1.07 (1.01 to 1.14) | 0.018 | 1.07 (1.01 to 1.14) | 0.021 | |
CRP (mg/L) | 0.98 (0.97 to 1.00) | 0.015 | 0.99 (0.97 to 1.00) | 0.040 | |
Jaw claudication | 3.04 (1.20 to 7.70) | 0.019 | 2.34 (0.85 to 6.43) | 0.099 | |
Abnormal MRA aorta | 0.27 (0.10 to 0.69) | 0.006 | 0.32 (0.12 to 0.89) | 0.028 | |